4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $753,662.36 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 58,333 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $12.92, for a total value of $753,662.36. Following the sale, the insider directly owned 709,153 shares in the company, valued at approximately $9,162,256.76. This trade represents a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

David Kirn also recently made the following trade(s):

• On Monday, September 14th, David Kirn sold 58,333 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $13.90, for a total value of $810,828.70.
• On Monday, August 3rd, David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.05, for a total value of $124,770.75.
• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.03, for a total value of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.87, for a total value of $548,364.96.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock traded up $0.03 on Wednesday, hitting $12.59. 603,567 shares of the company’s stock were exchanged, compared to its average volume of 855,943. The company has a 50 day moving average of $13.61 and a 200 day moving average of $11.34. The stock has a market cap of $695.47 million, a P/E ratio of -4.79 and a beta of 2.75. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. 4D Molecular Therapeutics, Inc. has a 12 month low of $6.96 and a 12 month high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. On average, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.07 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on FDMT. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target for the company in a report on Monday, September 14th. Chardan Capital dropped their price target on 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $28.90.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC acquired a new stake in 4D Molecular Therapeutics during the 2nd quarter worth approximately $76,466,000. BlackRock Inc. acquired a new position in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $60,463,000. Janus Henderson Group PLC increased its position in 4D Molecular Therapeutics by 13.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after acquiring an additional 611,276 shares during the period. Trails Edge Capital Partners LP bought a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $29,631,296. Finally, Bank of America Corp DE bought a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $14,905,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.